var data={"title":"Misoprostol: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Misoprostol: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6591?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=misoprostol-patient-drug-information\" class=\"drug drug_patient\">see &quot;Misoprostol: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5709091\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Women of childbearing potential:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Misoprostol administration to women who are pregnant can cause birth defects, abortion, premature birth, or uterine rupture. Uterine rupture has been reported when misoprostol was administered in pregnant women to induce labor or to induce abortion. The risk of uterine rupture increases with advancing gestational ages and with prior uterine surgery, including cesarean delivery. Misoprostol should not be taken by pregnant women to reduce the risk of ulcers induced by NSAIDs.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Patients must be advised of the abortifacient property and warned not to give the drug to others.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Misoprostol should not be used for reducing the risk of NSAID-induced ulcers in women of childbearing potential unless the patient is at high risk of complications from gastric ulcers associated with use of the NSAID, or is at high risk of developing gastric ulceration. In such patients, misoprostol may be prescribed if the patient has had a negative serum pregnancy test within 2 weeks prior to beginning therapy; is capable of complying with effective contraceptive measures; has received both oral and written warnings of the hazards of misoprostol, the risk of possible contraception failure, and the danger to other women of childbearing potential if the drug is taken by mistake; and will begin misoprostol only on the second or third day of the next normal menstrual period.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F197188\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Cytotec</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F197231\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Prostaglandin</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F197192\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>NSAID-induced gastric ulcers, prevention:</b> Oral: 200 mcg 4 times daily; if not tolerated, may decrease dose to 100 mcg 4 times daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Termination of intrauterine pregnancy:</b> Oral: Refer to Mifepristone monograph.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Early pregnancy loss (off-label use):</b> Intravaginal (off-label route): Initial dose: 800 mcg. May repeat with one dose if needed, &ge;3 hours after the first dose and typically within 7 days if no response to the initial dose is observed (ACOG 150 2015).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Incomplete abortion (treatment) (off-label use):</b> Oral: 600 mcg as a single dose (ACOG 427 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Labor induction or cervical ripening (off-label uses):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Intravaginal (off-label route): 25 mcg (one-fourth of 100 mcg tablet); may repeat at intervals no more frequent than every 3 to 6 hours; 50 mcg every 6 hours may be used in some cases (ACOG 107 2009).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: 25 mcg (one-fourth of 100 mcg tablet) every 2 hours (Tang 2013); 20 mcg doses every 2 hours have also been evaluated (Alfirevic 2014; Kundodyiwa 2009).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Note:</b> The vaginal route may be more efficient; however, some adverse events may occur less frequently when misoprostol is administered orally for this indication (ACOG 107 2009; Alfirevic 2014; Chen 2016; Kundodyiwa 2009). Sublingual and buccal routes should not be used for cervical ripening or induction of labor (ACOG 107 209). Additional data may be necessary to further define the optimal dose and route of administration.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Missed abortion (treatment) (off-label use):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Intravaginal (off-label route): 800 mcg; may repeat every 3 hours for 2 additional doses if needed (ACOG 427 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Sublingual (off-label route): 600 mcg; may repeat every 3 hours for 2 additional doses if needed (ACOG 427 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Postpartum hemorrhage (prevention) (off-label use): Note:</b> Side effects are associated with use and may be dose and route related (Leduc 2009; Ugwu 2016). Additional data may be necessary to further define the optimal dose and route of administration (Bolhmann 2014).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: 600 mcg as a single dose administered immediately after delivery (FIGO 2012a).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Postpartum hemorrhage (treatment) (off-label use): Note:</b> Side effects are associated with use and may be dose and route related (FIGO 2012b; Leduc 2009). Additional data may be necessary to further define the optimal dose and route of administration (Bolhmann 2014).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: 600 to 1,000 mcg as a single dose (ACOG 183 2017).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Rectal (off-label route): 600 to 1,000 mcg as a single dose (ACOG 183 2017).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Sublingual (off-label route): 800 mcg as a single dose. Use caution if a prophylactic dose was already given, especially if adverse events were observed (FIGO 2012b). Dosage ranges of 600 to 1,000 mcg as a single dose have been noted (ACOG 183 2017), however a lower 400 mcg dose has also been recommended (Leduc 2009).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46782803\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Termination of intrauterine pregnancy:</b> Oral: Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15976971\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>NSAID-induced gastric ulcers, prevention:</b> Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9660726\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">Dose adjustment is not routinely needed; however, the dose may be reduced if the recommended dose is not tolerated. It is not known if misoprostol is removed by dialysis.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15976866\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F197165\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cytotec: 100 mcg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cytotec: 200 mcg [scored]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 100 mcg, 200 mcg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F197151\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F197168\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Administer with food and avoid magnesium containing antacids (minimizes diarrhea); last dose of the day should be taken at bedtime. Therapy should continue through the duration of NSAID therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Termination of intrauterine pregnancy: Refer to Mifepristone monograph.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Labor induction or cervical ripening (off-label uses): Because the recommended doses require breaking of the commercially available tablets, some reports recommend weighing the tablet fragments (for oral or vaginal use) or preparing a solution (for oral use) to ensure accurate dosing (Alfirevic 2014; Williams 2002)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49104556\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (NIOSH 2016 [group 3]).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage. NIOSH recommends single gloving for administration of intact tablets or capsules (NIOSH 2016). Assess risk to determine appropriate containment strategy (USP-NF 2017).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F197167\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>NSAID-induced gastric ulcers, prevention:</b> To reduce the risk of NSAID-induced gastric ulcers in patients at high risk of complications</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Termination of intrauterine pregnancy:</b> Medical termination of intrauterine pregnancy through 70 days' gestation in combination with mifepristone (Mifeprex prescribing information March 2016)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25469219\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Cervical ripening and labor induction; Early pregnancy loss; Incomplete or missed abortion (treatment); Postpartum hemorrhage (prevention/treatment)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F197238\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cytotec may be confused with Cytoxan</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">MiSOPROStol may be confused with metoprolol, miFEPRIStone </p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F197158\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%: Gastrointestinal: Diarrhea, abdominal pain</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Headache</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Constipation, dyspepsia, flatulence, nausea, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Abnormal hepatobiliary function, alopecia, anaphylaxis, anemia, anxiety, arterial thrombosis, arthralgia, back pain, bronchitis, bronchospasm, cardiac arrhythmia, cerebrovascular accident, change in appetite, chest pain, chills, confusion, conjunctivitis, deafness, depression, dermatitis, diaphoresis, dizziness, drowsiness, dysgeusia, dysphagia, dyspnea, dysuria, edema, epistaxis, fatigue, fever, gastroesophageal reflux disease, gastrointestinal hemorrhage, GI inflammation, gingivitis, glycosuria, gout, gynecological disease (cramps, dysmenorrhea, hypermenorrhea, spotting, postmenopausal vaginal bleeding, and other menstrual disorders), hematuria, hypertension, hypotension, impotence, increased amylase, increased blood urea nitrogen, increased cardiac enzymes, increased erythrocyte sedimentation rate, increased serum alkaline phosphatase, increased thirst, loss of libido, mastalgia, muscle cramps, myalgia, myocardial infarction, neuropathy, otalgia, pallor, phlebitis, pneumonia, polyuria, psychoneurosis, pulmonary embolism, purpura, rigors, skin rash, stiffness, syncope, thrombocytopenia, tinnitus, upper respiratory tract infection, urinary tract infection, uterine rupture, visual disturbance, weakness, weight changes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F197171\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to misoprostol, other prostaglandins, or any component of the formulation; pregnancy</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">When used for termination of intrauterine pregnancy (additional contraindications): Refer to Mifepristone monograph.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F197155\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Abortifacient: <b>[US Boxed Warning]: Due to the abortifacient property of this medication, patients must be warned not to give this drug to others.</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular disease: Use with caution in patients with cardiovascular disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment; dosage adjustment may be needed.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pregnancy: Adverse events have been reported when used outside of current product labeling (cervical ripening, induction of labor, treatment of serious postpartum hemorrhage). Uterine tachysystole may occur and progress to uterine tetany; uteroplacental blood flow may be impaired and uterine rupture or amniotic fluid embolism leading to adverse fetal heart changes may occur. The risk of uterine rupture may be increased with advanced gestational age, grand multiparity, or prior uterine surgery (including cesarean delivery). Uterine activity and fetal status should be monitored in a hospital setting. Misoprostol should not be used in situations where uterotonic drugs are otherwise contraindicated or inappropriate.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Women of childbearing potential: <b>[US Boxed Warning]: Use of misoprostol during pregnancy may cause birth defects, abortion, premature birth, or uterine rupture. Uterine rupture has been reported when misoprostol was administered in pregnant women to induce labor or to induce abortion. The risk of uterine rupture increases with advancing gestational ages and with prior uterine surgery, including cesarean delivery. Misoprostol is not to be used to reduce the risk of NSAID-induced ulcers in woman of childbearing potential unless she is at risk of complications from gastric ulcers associated with NSAID use, or is at high risk of developing gastric ulceration. </b><b>In such patients, misoprostol may be prescribed if the patient has had a negative serum pregnancy test within 2 weeks prior to beginning therapy; is capable of complying with effective contraceptive measures; has received both oral and written warnings of the hazards of misoprostol, the risk of possible contraception failure, and the danger to other women of childbearing potential if the drug is taken by mistake; and will begin misoprostol only on the second or third day of the next normal menstrual period. </b> <b>Due to the abortifacient property of this medication, patients must be warned not to give this drug to others. </b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Termination of pregnancy: Misoprostol is approved for use with mifepristone for termination of pregnancy. Refer to mifepristone warnings, precautions, and contraindications for appropriate use of misoprostol for this indication.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Gastric ulcers: For use only in patients at high risk of complications from gastric ulcers (eg, elderly patients, patients with concomitant diseases) or patients at high risk for developing gastric ulcers (eg, those with a history of ulcers) taking NSAIDs. Misoprostol must be taken during the duration of NSAID therapy. It is not effective in preventing duodenal ulcers in patients taking NSAIDs.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299720\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F197160\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9657&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Antacids: May enhance the adverse/toxic effect of MiSOPROStol. More specifically, concomitant use with magnesium-containing antacids may increase the risk of diarrhea. Management: Avoid concomitant use of misoprostol and magnesium-containing antacids. In patients requiring antacid therapy, employ magnesium-free preparations. Monitor for increased adverse effects (e.g., diarrhea, dehydration).<b> Exceptions: </b>Aluminum Hydroxide; Calcium Carbonate; Potassium Bicarbonate; Sodium Bicarbonate.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Carbetocin: MiSOPROStol may enhance the adverse/toxic effect of Carbetocin. Specifically, Carbetocin oxytocic effects may be enhanced. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oxytocin: MiSOPROStol may enhance the adverse/toxic effect of Oxytocin. Specifically, oxytocic effects may be enhanced.  Management: The manufacturer of misoprostol recommends avoiding concomitant use with oxytocin.  Misoprostol may augment effects of oxytocin, particularly when given within 4 hours of oxytocin initiation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phenylbutazone: May enhance the neurotoxic effect of MiSOPROStol. Specifically, the combination may result in headache, dizziness, and transient diplopia.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F197184\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">Misoprostol peak serum concentrations may be decreased if taken with food (not clinically significant).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F197174\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;\">Use for the prevention of NSAID-induced gastric ulcers is contraindicated in pregnant women.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">\n      <b>[US Boxed Warning]: Use of misoprostol during pregnancy may cause birth defects, abortion, premature birth, or uterine rupture. Uterine rupture has been reported when misoprostol was administered in pregnant women to induce labor or to induce abortion. The risk of uterine rupture increases with advancing gestational ages and with prior uterine surgery, including cesarean delivery. Misoprostol is not to be used to reduce the risk of NSAID-induced ulcers in woman of childbearing potential unless she is at risk of complications from gastric ulcers associated with NSAID use, or is at high risk of developing gastric ulceration. In such patients, misoprostol may be prescribed if the patient has had a negative serum pregnancy test within 2 weeks prior to beginning therapy; is capable of complying with effective contraceptive measures; has received both oral and written warnings of the hazards of misoprostol, the risk of possible contraception failure, and the danger to other women of childbearing potential if the drug is taken by mistake; and will begin misoprostol only on the second or third day of the next normal menstrual period. Due to the abortifacient property of this medication, patients must be warned not to give this drug to others.</b></p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Congenital anomalies following first trimester exposure have been reported, including skull defects, cranial nerve palsies, facial malformations, and limb defects. Misoprostol may produce uterine contractions; fetal death, uterine perforation, and abortion may occur.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Misoprostol is FDA approved for the medical termination of pregnancy of &le;70 days in conjunction with mifepristone.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Because misoprostol may induce or augment uterine contractions, it has been used off-label as a cervical-ripening agent for induction of labor. Misoprostol should not be used for this purpose during the third trimester in conditions where a spontaneous labor and vaginal delivery would be contraindicated, including women who have had a prior cesarean delivery or major uterine surgery (because the risk of uterine rupture is increased) (ACOG 107 2009; ACOG 184 2017). It has also been used for the treatment of incomplete or missed abortion (ACOG 427 2009), early pregnancy loss (ACOG 150 2015), or severe postpartum hemorrhage (ACOG 183 2017; FIGO 2012a; FIGO 2012b). Some guidelines recommend misoprostol for postpartum hemorrhage only secondary to oxytocin in situations where oxytocin is not available (Leduc 2000; FIGO 2012a; FIGO 2012b). Various routes of administration have been used for postpartum hemorrhage. Sublingual administration has the most rapid onset, the oral route produces the most pronounced initial increase in tonus, and rectal and vaginal routes exhibit longer durations of action as compared to oral and sublingual routes (Leduc 2009). Adverse events associated with off-label obstetric uses include uterine tachysystole (may impair placental blood flow), uterine rupture, amniotic fluid embolism, or adverse fetal heart changes. Chills, fever, and/or shivering are commonly associated with use of sublingual misoprostol when used for postpartum hemorrhage; incidence of side effects may be dose related (FIGO 2012b).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F197175\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Misoprostol acid (the active metabolite of misoprostol) is present in breast milk. Adverse events have not been reported in breastfeeding infants (FIGO 2012a; FIGO 2012b). The manufacturer recommends that caution be used if administered to a breastfeeding woman.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F197176\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">When used for the prevention of NSAID-induced ulcers, take with food.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9660727\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prevention of NSAID-induced gastric ulcers: Pregnancy test in women of reproductive potential prior to therapy; adequate diagnostic measures in all cases of undiagnosed abnormal vaginal bleeding</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Off-label pregnancy-related uses: Uterine activity and fetal status. When used for incomplete or missed abortion, reevaluate 1 to 2 weeks after dosing (ACOG 427 2009). When used for termination of pregnancy: Prior to procedure, confirm pregnancy and Rh status; assess hemoglobin and hematocrit if anemia is suspected (ACOG 2014). Following procedure: Clinical exam, human Chorionic Gonadotropin (hCG) testing, and/or ultrasound to confirm complete termination of pregnancy; hemoglobin, hematocrit, and red blood cell count in cases of heavy bleeding. Consider CBC in any patient who reports nausea, vomiting, or diarrhea and weakness with or without abdominal pain, and without fever or other signs of infection more than 24 hours after administration of misoprostol (Mifeprex prescribing information March 2016).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F197154\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Misoprostol is a synthetic prostaglandin E<sub>1</sub> analog that replaces the protective prostaglandins consumed with prostaglandin-inhibiting therapies (eg, NSAIDs); has been shown to induce uterine contractions</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F197170\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action: Inhibition of gastric acid secretion: 30 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Duration of action: Inhibition of gastric acid secretion: 3 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Rapid and extensive; extensive; food decreases absorption of misoprostol acid</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: Misoprostol acid: &lt;90%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Hepatic; rapid de-esterification to misoprostol acid (active)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: Misoprostol acid: 20 to 40 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, serum: Misoprostol acid: Fasting: 12 &plusmn; 3 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (80%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F197173\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Cytotec Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mcg (100): $476.52</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mcg (100): $661.56</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (MiSOPROStol Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mcg (60): $49.45</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mcg (100): $142.00</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F197177\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Aboprost (IN);</li>\n      <li>Alsoben (KR, VN);</li>\n      <li>Asotec (BD);</li>\n      <li>Chromalux (ID);</li>\n      <li>Cyprostil (PT);</li>\n      <li>Cyprostol (AT);</li>\n      <li>Cyrux (CR, DO, GT, HN, MX, NI, PA, SV);</li>\n      <li>Cytil (CO);</li>\n      <li>Cytolog (IN);</li>\n      <li>Cytotec (AE, AU, BB, BE, BF, BG, BH, BJ, BR, CH, CI, CN, CR, CY, DE, DK, EC, ES, FI, FR, GB, GH, GM, GN, GR, HK, HN, IE, IL, IQ, IR, IS, IT, JO, JP, KE, KR, KW, LB, LR, LU, LY, MA, ML, MR, MT, MU, MW, MX, MY, NE, NG, NI, NL, NO, NZ, OM, PA, PE, PL, PT, QA, RU, SA, SC, SD, SE, SG, SI, SL, SN, SV, SY, TH, TN, TR, TW, UG, VE, YE, ZA, ZM, ZW);</li>\n      <li>Dazitum (PT);</li>\n      <li>Gastrul (ID);</li>\n      <li>Gymiso (AU, FR);</li>\n      <li>Herwont (IN);</li>\n      <li>Invitec (ID);</li>\n      <li>Isovent (BD);</li>\n      <li>Mipros (ID);</li>\n      <li>Mirolut (RU);</li>\n      <li>Misel (KR, SG);</li>\n      <li>Miso-Fem (ET);</li>\n      <li>Misoclear (BD, TZ);</li>\n      <li>Misodel (AT, AU, CH, DE, DK, ES, FI, HU, IL, IS, LT, LV, MT, NL, NO, PL, PT, RO, SE, SG, SK);</li>\n      <li>Misodex (IT);</li>\n      <li>Misofar (ES);</li>\n      <li>MisoOne (BG);</li>\n      <li>Misoone (ES, LV);</li>\n      <li>Misopa (BD);</li>\n      <li>Misopess (AU);</li>\n      <li>Misoprost (IN);</li>\n      <li>Misoprost-200 (ZW);</li>\n      <li>Misotrol (CL);</li>\n      <li>Mispregnol (CZ, HR, SK);</li>\n      <li>Misprolen (PE);</li>\n      <li>Misprosmek (PE);</li>\n      <li>Mizoprost (UA);</li>\n      <li>Mizotab (UA);</li>\n      <li>Mysodelle (BE, EE, GB);</li>\n      <li>Myspess (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Mystol (PE);</li>\n      <li>Noprostol (ID);</li>\n      <li>Prosomed (ID);</li>\n      <li>Taneciprol (MX);</li>\n      <li>Topogyne (EE, GB, RO);</li>\n      <li>U-Miso (TW);</li>\n      <li>Vagiprost (EG)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    &lt;800&gt; Hazardous Drugs&mdash;Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary</i> (USP 40-NF 35). Rockville, MD: United States Pharmacopeia Convention; 2017:83-102.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Alfirevic Z, Aflaifel N, Weeks A. Oral misoprostol for induction of labour. <i>Cochrane Database Syst Rev.</i> 2014;(6):CD001338. doi: 10.1002/14651858.CD001338.pub3.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/misoprostol-drug-information/abstract-text/24924489/pubmed\" target=\"_blank\" id=\"24924489\">24924489</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"25932865\"></a>American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 150. Early pregnancy loss. <i>Obstet Gynecol</i>. 2015;125(5):1258-1267.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/misoprostol-drug-information/abstract-text/25932865/pubmed\" target=\"_blank\" id=\"25932865\">25932865</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"19155922\"></a>American College of Obstetricians and Gynecologists. ACOG Committee Opinion No. 427: Misoprostol for Postabortion Care. <i>Obstet Gynecol</i>. 2009;113(2, pt 1):465-468.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/misoprostol-drug-information/abstract-text/19155922/pubmed\" target=\"_blank\" id=\"19155922\">19155922</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American College of Obstetricians and Gynecologists (ACOG). Committee on Practice Bulletins-Obstetrics. Practice Bulletin No. 183: Postpartum hemorrhage. <i>Obstet Gynecol.</i> 2017;130(4):e168-e186. doi:10.1097/AOG.0000000000002351.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/misoprostol-drug-information/abstract-text/28937571/pubmed\" target=\"_blank\" id=\"28937571\">28937571</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"19623003\"></a>American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 107: Induction of Labor. <i>Obstet Gynecol</i>. 2009;114(2, pt 1):386-397.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/misoprostol-drug-information/abstract-text/19623003/pubmed\" target=\"_blank\" id=\"19623003\">19623003</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American College of Obstetricians and Gynecologists (ACOG). Committee on Practice Bulletins-Obstetrics. Practice Bulletin No. 184: Vaginal Birth After Cesarean Delivery. <i>Obstet Gynecol</i>. 2017;130(5):e217-e233. doi: 10.1097/AOG.0000000000002398.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/misoprostol-drug-information/abstract-text/29064970/pubmed\" target=\"_blank\" id=\"29064970\">29064970</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American College of Obstetricians and Gynecologists (ACOG). Practice bulletin no. 143: medical management of first-trimester abortion. <i>Obstet Gynecol</i>. 2014;123(3):676-692.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/misoprostol-drug-information/abstract-text/24553166/pubmed\" target=\"_blank\" id=\"24553166\">24553166</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bohlmann MK, Rath W. Medical prevention and treatment of postpartum hemorrhage: a comparison of different guidelines. <i>Arch Gynecol Obstet.</i> 2014;289(3):555-567. doi: 10.1007/s00404-013-3016-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/misoprostol-drug-information/abstract-text/24006033/pubmed\" target=\"_blank\" id=\"24006033\">24006033</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chen W, Xue J, Peprah MK, et al. A systematic review and network meta-analysis comparing the use of Foley catheters, misoprostol, and dinoprostone for cervical ripening in the induction of labour. <i>BJOG.</i> 2016;123(3):346-354. doi: 10.1111/1471-0528.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/misoprostol-drug-information/abstract-text/26538408/pubmed\" target=\"_blank\" id=\"26538408\">26538408</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cleghorn GJ, Shepherd RW, Holt TL. The Use of a Synthetic Prostaglandin E1 Analogue (Misoprostol) as an Adjunct to Pancreatic Enzyme Replacement in Cystic Fibrosis. <i>Scand J Gastroenterol Suppl</i>. 1988;143:142-147.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/misoprostol-drug-information/abstract-text/3133753/pubmed\" target=\"_blank\" id=\"3133753\">3133753</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cytotec (misoprostol) [prescribing information]. New York, NY: Pfizer; January 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    FIGO Working Group on Prevention of Unsafe Abortion and its Consequences; International Federation of Gynecology and Obstetrics. The combination of mifepristone and misoprostol for the termination of pregnancy [published correction appears in <i>Int J Gynaecol Obstet.</i> 2011;115(3):332]. <i>Int J Gynaecol Obstet.</i> 2011;115(1):1-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/misoprostol-drug-information/abstract-text/21872858/pubmed\" target=\"_blank\" id=\"21872858\">21872858</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"23022109\"></a>International Federation of Gynecology and Obstetrics (FIGO). Prevention of Postpartum Hemorrhage With Misoprostol. <i>Int J Gynaecol Obstet</i>. 2012a;119(3):213-214.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/misoprostol-drug-information/abstract-text/23022109/pubmed\" target=\"_blank\" id=\"23022109\">23022109</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"23036964\"></a>International Federation of Gynecology and Obstetrics (FIGO). Treatment of Postpartum Hemorrhage With Misoprostol. <i>Int J Gynaecol Obstet</i>. 2012b;119(3):215-216.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/misoprostol-drug-information/abstract-text/23036964/pubmed\" target=\"_blank\" id=\"23036964\">23036964</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kundodyiwa TW, Alfirevic Z, Weeks AD. Low-dose oral misoprostol for induction of labor: a systematic review. <i>Obstet Gynecol.</i> 2009;113(2 Pt 1):374-383. doi: 10.1097/AOG.0b013e3181945859.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/misoprostol-drug-information/abstract-text/19155909/pubmed\" target=\"_blank\" id=\"19155909\">19155909</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Leduc D, Senikas V, Lalonde AB, et al; Clinical Practice Obstetrics Committee; Society of Obstetricians and Gynaecologists of Canada. Active management of the third stage of labour: prevention and treatment of postpartum hemorrhage. <i>J Obstet Gynaecol Can</i>. 2009;31(10):980-93. Review.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/misoprostol-drug-information/abstract-text/19941729/pubmed\" target=\"_blank\" id=\"19941729\">19941729</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mifeprex (mifepristone) [prescribing information]. New York, NY: Danco Laboratories; March 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Robinson PJ, Smith AL, Sly PD. Duodenal pH in Cystic Fibrosis and Its Relationship to Fat Malabsorption. <i>Dig Dis Sci</i>. 1990;35(10):1299-1304.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/misoprostol-drug-information/abstract-text/2120019/pubmed\" target=\"_blank\" id=\"2120019\">2120019</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tang J, Kapp N, Dragoman M, et al. WHO recommendations for misoprostol use for obstetric and gynecologic indications.<i> Int J Gynaecol Obstet.</i> 2013;121(2):186-189. doi: 10.1016/j.ijgo.2012.12.009.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/misoprostol-drug-information/abstract-text/23433680/pubmed\" target=\"_blank\" id=\"23433680\">23433680</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ugwu IA, Oluwasola TA, Enabor OO, et al. Randomized controlled trial comparing 200&mu;g and 400&mu;g sublingual misoprostol for prevention of primary postpartum hemorrhage. <i>Int J Gynaecol Obstet.</i> 2016;133(2):173-177. doi: 10.1016/j.ijgo.2015.09.026.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/misoprostol-drug-information/abstract-text/26892695/pubmed\" target=\"_blank\" id=\"26892695\">26892695</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 5, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Walt RP. Misoprostol for the Treatment of Peptic Ulcer and Anti-inflammatory Drug-Induced Gastroduodenal Ulceration. <i>N Engl J Med</i>. 1992;327(22):1575-1580.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/misoprostol-drug-information/abstract-text/1435885/pubmed\" target=\"_blank\" id=\"1435885\">1435885</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wing DA. Labor Induction With Misoprostol. <i>Am J Obstet Gynecol</i>. 1999;181(2):339-345.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/misoprostol-drug-information/abstract-text/10454679/pubmed\" target=\"_blank\" id=\"10454679\">10454679</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9657 Version 158.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5709091\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F197188\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F197231\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F197192\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F46782803\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F15976971\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F9660726\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F15976866\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F197165\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F197151\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F197168\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49104556\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F197167\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25469219\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F197238\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F197158\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F197171\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F197155\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299720\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F197160\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F197184\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F197174\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F197175\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F197176\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F9660727\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F197154\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F197170\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F197173\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F197177\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9657|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=misoprostol-patient-drug-information\" class=\"drug drug_patient\">Misoprostol: Patient drug information</a></li></ul></div></div>","javascript":null}